Phillip Chan Biography and Net Worth
Dr. Phillip Chan is the CEO and President of CytoSorbents Corporation. Prior to CytoSorbents, Dr. Chan led healthcare and life science investments as Partner for the $80M NJTC Venture Fund, one of the top performing and largest early stage investors in the greater New York region. He was responsible for numerous investments in therapeutics, medical devices and diagnostics. Dr. Chan also co-founded Andrew Technologies, a venture-backed medical device company commercializing its FDA approved HydraSolve™ advanced lipoplasty system in the U.S. Dr. Chan received Board-certification in internal medicine, having completed his residency at Harvard Medical School at the Beth Israel Deaconess Medical Center. Dr. Chan received his MD/PhD from Yale University School of Medicine and his BS in cell and molecular biology from Cornell University. In 2012, Dr. Chan was named an Ernst & Young New Jersey Entrepreneur-of-the-Year finalist.
What is Phillip P. Chan's net worth?
The estimated net worth of Phillip P. Chan is at least $1.21 million as of September 8th, 2022. Dr. Chan owns 867,279 shares of Cytosorbents stock worth more than $1,205,518 as of September 28th. This net worth estimate does not reflect any other assets that Dr. Chan may own. Additionally, Dr. Chan receives a salary of $667,470.00 as CEO at Cytosorbents. Learn More about Phillip P. Chan's net worth.
How old is Phillip P. Chan?
What is Phillip P. Chan's salary?
As the CEO of Cytosorbents Co., Dr. Chan earned a total compensation package of $1,790,596.00 in 2021. Dr. Chan earned a salary of $482,851.00, a bonus of $172,619.00, stock awards of $647,280.00, options awards of $475,846.00, and other compensation of $12,000.00. Learn More on Phillip P. Chan's salary.
How do I contact Phillip P. Chan?
Has Phillip P. Chan been buying or selling shares of Cytosorbents?
During the past quarter, Phillip P. Chan has bought $59,500.00 in shares of Cytosorbents stock. Most recently, on Thursday, September 8th, Phillip P. Chan bought 35,000 shares of Cytosorbents stock. The stock was acquired at an average cost of $1.70 per share, with a total value of $59,500.00. Following the completion of the transaction, the chief executive officer now directly owns 867,279 shares of the company's stock, valued at $1,474,374.30. Learn More on Phillip P. Chan's trading history.
Who are Cytosorbents' active insiders?
Are insiders buying or selling shares of Cytosorbents?
During the last twelve months, Cytosorbents insiders bought shares 12 times. They purchased a total of 83,597 shares worth more than $185,613.09. The most recent insider tranaction occured on September, 8th when CEO Phillip P Chan bought 35,000 shares worth more than $59,500.00. Insiders at Cytosorbents own 7.0 % of the company. Learn More about insider trades at Cytosorbents.
Information on this page was last updated on 9/8/2022.
Phillip P. Chan Insider Trading History at Cytosorbents
|Transaction Date||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
Cytosorbents Company Overview
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. Its flagship product is CytoSorb, an extracorporeal cytokine filter for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention and treatment of perioperative complications of cardiopulmonary bypass surgery, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant. The company also develops VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals; CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, as well as removal of anti-A and anti-B blood group antibodies from fresh whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it is involved in the development of BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove toxic chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.
50 Day Range
2 Week Range